Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab vs Azathioprine for Maintenance of Remission in EGPA
NCT03164473Phase 3Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Mar 2018
- Primary completion
- Sep 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of rituximab in eosinophilic granulomatosis with polyangiitis (EGPA), sponsored by Assistance publique - Hôpitaux de Paris. Started Mar 2018; status: completed.
02
Drugs
rituximab
03
Conditions
eosinophilic granulomatosis with polyangiitis (EGPA)
Beyond the preview
Go deeper on NCT03164473.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03164473.